

AMENDMENTS TO THE CLAIMS

This listing of Claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-48. (Cancelled)

49. (Currently Amended) A purified polypeptide the amino acid sequence of which comprises SEQ ID NO: 2, or a ~~degenerate~~ variant of SEQ ID NO: 2 having at least one of bacteriolytic activity and glycosidase activity.
50. (Currently Amended) The purified polypeptide of claim 49 where said variant is a fragment, said fragment comprising at least 6 ~~[[5]]~~ consecutive amino acids, wherein said polypeptide is immunologically reactive with an anti-GBS phage lysin antibody.
51. (Previously Presented) The purified polypeptide of claim 49 where said sequence comprises an amino acid sequence which is at least 80% identical to SEQ ID NO: 2.
52. (Previously Presented) The purified polypeptide of claim 49 where said sequence comprises an amino acid sequence which is at least 60% identical to SEQ ID NO: 2.
53. (Previously Presented) The purified polypeptide of claim 49 where said variant is a fragment, said fragment comprising an amino acid sequence selected from the group consisting of: residues 1-107, residues 6-107, residues 6-443, residues 1-

344, residues 145-344, residues 145-443 and residues 6-344, where the polypeptide express at least one of an endopeptidase or a glycosidase activity.

54. (Currently Amended) The purified polypeptide of claim 49 where said variant is a mutant, ~~said mutant being characterized as having~~ has at least one of the following characteristics: (i) having a serine residue at position 26; (ii) having a serine residue at position 44; or (iii) having a serine residue at position 26 and position 44.
55. (Previously Presented) The purified polypeptide of claim 54 where said variant does not express an endopeptidase activity.
56. (New) The purified polypeptide of claim 49 where said variant is at least 93% identical to SEQ ID NO: 2.
57. (New) The purified polypeptide of claim 56 where said variant is at least 95% identical to SEQ ID NO: 2.
58. (New) A purified polypeptide the amino acid sequence of which comprises SEQ ID NO: 2, or a variant of SEQ ID NO: 2 that is at least 93% identical to SEQ ID NO: 2.
59. (New) The purified polypeptide of claim 58 where said variant is at least 95% identical to SEQ ID NO: 2.
60. (New) The purified polypeptide of claim 58 wherein said polypeptide is immunologically reactive with an anti-GBS phage lysin antibody.
61. (New) The purified polypeptide of claim 58 where said variant comprises an amino acid sequence selected from the group consisting of: residues 1-107,

residues 6-107, residues 6-443, residues 1-344, residues 145-344, residues 145-443 and residues 6-344.

62. (New) The purified polypeptide of claim 58 where said variant has at least one of the following characteristics: (i) having a serine residue at position 26; (ii) having a serine residue at position 44; or (iii) having a serine residue at position 26 and position 44.
63. (New) The purified polypeptide of claim 62 where said variant does not express an endopeptidase activity.
64. (New) A purified polypeptide the amino acid sequence of which comprises SEQ ID NO: 2, or a fragment of SEQ ID NO: 2.
65. (New) The purified polypeptide of claim 64, said fragment comprising at least 6 consecutive amino acids, wherein said polypeptide is immunologically reactive with an anti-GBS phage lysin antibody.
66. (New) The purified polypeptide of claim 64, said fragment comprising an amino acid sequence selected from the group consisting of: residues 1-107, residues 6-107, residues 6-443, residues 1-344, residues 145-344, residues 145-443 and residues 6-344, where the polypeptide express at least one of an endopeptidase or a glycosidase activity.
67. (New) The purified polypeptide of claim 64 being characterized as having at least one of the following characteristics: (i) having a serine residue at position 26; (ii) having a serine residue at position 44; or (iii) having a serine residue at position 26 and position 44.

68. (New) The purified polypeptide of claim 67 where said variant does not express an endopeptidase activity.